Aquatic Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Aquatic Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.31M	Sell	38,293 -40,906	-52%	-$2.27M	0.08%	325
2026 Q1	$4.61M	Buy	+79,199	New	+$3.65M	0.13%	204
2025 Q2	–	Sell	-10,511	Closed	-$353K	–	1595
2025 Q1	$353K	Buy	10,511 +2,251	+27%	+$85.5K	0.01%	824
2024 Q4	$324K	Buy	+8,260	New	+$342K	0.01%	828
2024 Q3	–	Sell	-4,200	Closed	-$164K	–	1594
2024 Q2	$164K	Sell	4,200 -20,500	-83%	-$819K	0.01%	801
2024 Q1	$1.06M	Buy	24,700 +5,200	+27%	+$239K	0.03%	376
2023 Q4	$898K	Buy	19,500 +4,200	+27%	+$148K	0.02%	499
2023 Q3	$523K	Buy	+15,300	New	+$572K	0.02%	472
2023 Q2	–	Sell	-2,000	Closed	-$72K	–	1792
2023 Q1	$72K	Buy	+2,000	New	+$73.9K	﹤0.01%	817
2022 Q2	–	Sell	-400	Closed	-$12K	–	1614
2022 Q1	$12K	Sell	400 -5,000	-93%	-$150K	0.02%	627
2021 Q4	$169K	Buy	+5,400	New	+$161K	0.33%	52

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Aquatic Capital Management's XENE Position: Q2 2026 in Review

Aquatic Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 52% in Q2 2026, selling an estimated $2.27M and leaving 38,293 shares worth $2.31M. The position accounts for 0.08% of the portfolio, ranked #325.

Aquatic Capital Management first reported a position in XENE in Q4 2021 and has held it in 11 quarters since. The position peaked at $4.61M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Aquatic Capital Management held 38,293 shares of Xenon Pharmaceuticals worth $2.31M as of Q2 2026.
Aquatic Capital Management sold 40,906 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
Xenon Pharmaceuticals made up 0.08% of Aquatic Capital Management's portfolio in Q2 2026, its #325 holding.
Aquatic Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Aquatic Capital Management's Xenon Pharmaceuticals position peaked at $4.61M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.